The results of the KEYNOTE-859 trial demonstrated that pembrolizumab in combination with CTH (capecitabine plus oxaliplatin or fluorouracil plus cisplatin) is an effective and well-tolerated first-line treatment for patients with locally advanced or metastatic HER2-negative GC or GEJ. This evidence concerns the gene ERBB2 and gastric cancer.